Insider · CIK 0001554591

Jagpal Sukhi

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001554591

Forms 4 and 5

Insider transactions

41 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-05	STROSUTRO BIOPHARMA, INC. · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2025-12-23	STROSUTRO BIOPHARMA, INC. · Stock Option (right to buy)A Award	Director	AAward	+1,500 sh	—	—	1,500
2025-06-06	STROSUTRO BIOPHARMA, INC. · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2024-08-08	STROSUTRO BIOPHARMA, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+35K sh	—	—	35,000
2024-08-08	STROSUTRO BIOPHARMA, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+29K sh	—	—	28,959
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−3,859 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−1,218 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−4,200 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−1,750 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−4,509 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−5,000 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−94.1K sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−49K sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−5,887 sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−30K sh	—	—	0
2022-07-01	Sierra Oncology, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−50K sh	—	—	0
2022-06-17	Sierra Oncology, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+12.3K sh	—	—	12,250
2022-03-14	Sierra Oncology, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+50K sh	—	—	50,000
2022-01-28	Sierra Oncology, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+12.3K sh	—	—	12,250
2021-03-15	Sierra Oncology, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+30K sh	—	—	30,000
2020-08-12	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+5,887 sh	—	—	5,887
2020-02-25	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+94.1K sh	—	—	94,113
2019-03-04	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+200K sh	—	—	200,000
2018-03-06	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+180K sh	—	—	180,360
2017-03-06	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+70K sh	—	—	70,000
2016-09-30	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+168K sh	—	—	168,000
2016-03-08	Sierra Oncology, Inc.Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+48.8K sh	—	—	48,750
2013-07-15	NOVELION THERAPEUTICS INC.Employee Stock Options (right to buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000
2013-05-14	NOVELION THERAPEUTICS INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$7.12	+$71.2K	11,200
2013-05-14	NOVELION THERAPEUTICS INC.S Sale	Chief Financial Officer	SSale	−9,900 sh	$7.95	−$78.7K	1,300
2013-05-14	NOVELION THERAPEUTICS INC.S Sale	Chief Financial Officer	SSale	−100 sh	$7.96	−$796	1,200
2013-05-14	NOVELION THERAPEUTICS INC.Employee Stock Options (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10K sh	—	—	0
2012-08-03	NOVELION THERAPEUTICS INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+20K sh	$3.74	+$74.8K	21,200
2012-08-03	NOVELION THERAPEUTICS INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15K sh	$2.44	+$36.6K	36,200
2012-08-03	NOVELION THERAPEUTICS INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12K sh	$6.28	+$75.4K	48,200
2012-08-03	NOVELION THERAPEUTICS INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+20K sh	$7.21	+$144K	68,200
2012-08-03	NOVELION THERAPEUTICS INC.S Sale	Chief Financial Officer	SSale	−67K sh	$8.19	−$549K	1,200
2012-08-03	NOVELION THERAPEUTICS INC.Employee Stock Options (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−20K sh	—	—	0
2012-08-03	NOVELION THERAPEUTICS INC.Employee Stock Options (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−15K sh	—	—	0
2012-08-03	NOVELION THERAPEUTICS INC.Employee Stock Options (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12K sh	—	—	0
2012-08-03	NOVELION THERAPEUTICS INC.Employee Stock Options (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−20K sh	—	—	0

Recent filings

Accepted (ET)
Jun 94
Jagpal Sukhi0001554591-26-000002
SEC(opens sec.gov)
Dec 294
Jagpal Sukhi0001554591-25-000004
SEC(opens sec.gov)
Jun 104
Jagpal Sukhi0001415889-25-016466
SEC(opens sec.gov)
Aug 124
Jagpal Sukhi0001415889-24-021089
SEC(opens sec.gov)
Jul 14
Jagpal Sukhi0001209191-22-040271
SEC(opens sec.gov)
Jun 174
Jagpal Sukhi0001209191-22-037841
SEC(opens sec.gov)
Mar 144
Jagpal Sukhi0001209191-22-018490
SEC(opens sec.gov)
Jan 284
Jagpal Sukhi0001209191-22-005480
SEC(opens sec.gov)
Mar 174
Jagpal Sukhi0001209191-21-021619
SEC(opens sec.gov)

Companies

Address

C/O SUTRO BIOPHARMA, INC. 111 OYSTER POINT BOULEVARD

SOUTH SAN FRANCISCO, CA, 94080